Prakt. lékáren. 2016; 12(2): 54-57 | DOI: 10.36290/lek.2016.014
Chronic venous disease - detective story for doctors, patients and pharmacists
- Dermal Centre Mělník
Chronic venous disease (CVD) is among civilization diseases. The pathophysiology is mainly venous inflammation, which causes
damage and valve regurgitation, giving rise to morphological and functional changes in the veins and venous reflux development,
which leads to increasing venous hypertension. CVD is a set of different clinical manifestations, the patient turns both to
physicians and to pharmacists. Due to the progressive character of it is reasonable to start with adequate treatment as soon as
possible. The treatments include compression stockings or elastic bandages, lifestyle changes, use of drugs and application of
local treatment. Surgical methods play important role. By combining efforts of physicians and pharmacists to patients with CVD,
educating and motivating them to adhere to recommended treatments, we can reduce the high percentage of untreated patients
with CVD, delay the progression of venous disease and reduce the prevalence of higher stages of this disease.
Keywords: chronic venous disease, venoactive drugs, compression therapy
Published: May 1, 2016 Show citation
References
- Pirkl M. Současné možnosti léčby chronické žilní nemoci pohledem žilního chirurga aneb Co by si mohl praktický lékař přečíst, než odešle pacienta k chirurgovi, Servier, 2015.
- Rabe E, et al. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. International Angiology 2012; 31(2): 105-115.
- Vojtíšková J. Czech Vein Program - výsledky epidemiologického programu. Praktická flebologie 2012; 21: 8-13.
- Tsoukanov YT, Tsoukanov AY, Nikolaychuk A. Great saphenous vein transitory reflux in patients with symptoms related to chronic venous disorders but without visible signs (C0s), and its correction with MPFF treatment. Phlebolymphology. 2015; 22(1): 18-24.
- Takase S, et al. Venous hypertension, inflammation and valve remodeling. Eur J Vasc Endovasc Surg. 2004; 28: 484-493.
Go to original source... 
Go to PubMed... - Pascarella L, Lulic D, Penn AH, et al. Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg. Eur J Vasc Endovasc Surg. 2008; 35(1): 102-110. Go to original source... Go to PubMed...
- Carpentier PH, et al. Prevalence, risk factors and clinical patterns of chronic venous disorders of lower limbs: a population-based study in France. J Vasc Surg. 2004; 40: 650-659. Go to original source... Go to PubMed...
- Slonková S, Vašků V. Kvalita života, sociálně-ekonomické aspekty bércových vředů a nové možnosti celkové terapie. Dermatologie pro praxi. 2014; 8(3): 89-92.
- Boisseau MR. Chronic venous disease and the genetic influence. Phlebolymphology. 2013; 21(2): 100-109.
- Navrátilová Z. Role venofarmak v terapii chronické žilní choroby. Medical Tribune. 2014; 11.
- Pospíšilová A, Hakl M. Bolest dolních končetin - žilní příčiny. Acta medicinae. 2015; 8: 3-6.
- Nicolaides AN, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol. 2014; 33(2): 87-208. Go to PubMed...
- Perrin M. Efficacy of vasoactive drugs in primary chronic venous disease survey of evidence, synthesis, and recommendations. In:Bergan JJ, Bunke N (eds) et al. The Vein Book. 2nd ed. Oxford University Press. 2014: 514-527. ISBN 978-0-19-539963-9.
- Pokrovsky AV, Saveljev VS, Kirienko AI, et al. Stripping of the great saphenous vein under micronized purified flavonoid fraction (MPFF) protection (results of the Russian multicenter controlled trial DEFANCE). Phlebolymphology. 2008; 15(2): 45-51.
- Veverkova L, Jedlicka V, Wechsler J, et al. Analysis of the various procedures used in great saphenous vein surgery in the Czech Republic and benefit of Daflon 500 mg to postoperative symptoms. Phlebolymphology. 2006; 13(4): 181-220.
- Pitsch F. Benefit of Daflon 500 mg in combination with sclerotherapy of teleangiectasias of the lower limbs: results form the SYNERGY and SATISFY surveys. Phlebolymphology. 2011; 19(4): 182-187.
- Bogachev VY, Golovanova OV, Kuznetsov AN, et al. Can Micronized Purified Flavonoid Fraction (MPFF) improve outcomes of lower extremity varicose vein endovenous treatment? First results from DECISION study. Phlebolypmphology. 2013; 20(4): 181-187.
- Crebassa V, Karihuel J. Micronized Purified Flavonoid Fraction Treatment Improves Cutaneous Outcomes and Patient's Satisfaction with Sclerotherapy for Superficial Varicosities. Int Angiol. 2013; 32(5 Suppl 1): 105.
- Hnátek L. Terapeutický potenciál mikronizované purifikované flavonoidní frakce (MPFF) diosminu a hesperidinu v rámci léčby chronického žilního onemocnění. Vnitřní lékařství. 2015; 61(9): 807-814. Go to PubMed...
- Végh V. Doplňky stravy vs. léčivé přípravky - praktické a právní aspekty. Praktická flebologie. 2012; 21: 3-7.
- Suchopár J, Prokeš M. Léčebné metody užívané u nemocných s chronický žilním onemocněním a adherence pacientů k těmto metodám v běžné klinické praxi v ČR, Practicus, 2015; 14(7): 12-17.
- Andreozzi GM, et al. Effects of elastic stocking on quality of life of patients with chronic venous insufficiency An Italian pilot study on Triveneto Region. International Angiology. 2005; 24(4): 325-329.
- Navrátilová Z. Léčba příznaků a projevů chronické žilní insuficience dolních končetin. Dermatologie pro praxi. 2015; 9(4): 157-161.
- Stryja J, et al. Repetitorium hojení ran 2, Geum. 2011: 261-263. ISBN 978-80-86256-79-5.